Key result
Dopaminergic agents linked to serotonin syndrome in 2 stroke patients, resolving after drug discontinuation.
Why the study?
Serotonin syndrome is a potentially life-threatening condition that can occur in stroke patients receiving dopaminergic agents, but awareness in this population is limited.
Case Report (n=2)
Dopaminergic agents such as ropinirole and carbidopa/levodopa can trigger potentially life-threatening serotonin syndrome in stroke patients, necessitating careful clinical monitoring.
May warrant vigilance with dopaminergic agents in stroke; case reports leave open need for prospective confirmation.
OBJECTIVE: Serotonin syndrome is a potentially life-threatening condition that can be caused by administration of agents that increase serotonergic activity in the brain. We report here on 2 stroke patients who presented with serotonin syndrome following administration of dopaminergic agents. CASE REPORT: Two stroke patients were administered ropinirole (patient 1) and carbidopa/levodopa (patient 2) during rehabilitation. Both patients exhibited the clinical features of serotonin syndrome, coinciding with an increase in dosage of each drug. Based on the clinical features included in revised Radomski's criteria, they presented with 3 major symptoms with 3 and 2 minor symptoms, respectively. The drugs that were thought to trigger serotonin syndrome were discontinued and the patients underwent conservative treatment. The patients recovered completely from the symptoms of serotonin syndrome appearing 2 days after administration of the trigger drugs. CONCLUSION: Because a considerable number of stroke patients have some limitation in communication, and serotonin syndrome is a potentially life-threatening condition, clinicians should pay particular attention to the potential for development of serotonin syndrome when prescribing these drugs to stroke patients.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2015) conducted a case report in stroke (n=2). dopaminergic agents (ropinirole and carbidopa/levodopa) was evaluated on serotonin syndrome. Administration of dopaminergic agents triggered serotonin syndrome in 2 stroke patients, with complete recovery occurring 2 days after discontinuing the trigger drugs.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: